76.97
4.27%
-3.43
After Hours:
76.97
Biomarin Pharmaceutical Inc. stock is currently priced at $76.97, with a 24-hour trading volume of 3.85M.
It has seen a -4.27% decreased in the last 24 hours and a -15.30% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $80.99 pivot point. If it approaches the $76.73 support level, significant changes may occur.
Previous Close:
$80.40
Open:
$80.18
24h Volume:
3.85M
Market Cap:
$14.62B
Revenue:
$2.47B
Net Income/Loss:
$205.46M
P/E Ratio:
100.13
EPS:
0.7687
Net Cash Flow:
$163.21M
1W Performance:
-5.81%
1M Performance:
-15.30%
6M Performance:
-11.74%
1Y Performance:
-16.36%
Biomarin Pharmaceutical Inc. Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc.
Sector
Industry
Phone
415-506-6700
Address
770 Lindaro Street, San Rafael, CA
Biomarin Pharmaceutical Inc. Stock (BMRN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-15-23 | Initiated | Wells Fargo | Overweight |
Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
Sep-28-23 | Initiated | Raymond James | Mkt Perform |
Sep-18-23 | Initiated | UBS | Buy |
Jul-27-23 | Initiated | Scotiabank | Sector Perform |
Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jun-14-23 | Resumed | Credit Suisse | Outperform |
Mar-21-23 | Initiated | Bernstein | Underperform |
Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
Feb-21-23 | Initiated | Citigroup | Neutral |
Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
Jan-18-23 | Initiated | Canaccord Genuity | Hold |
Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
Jun-13-22 | Resumed | Wedbush | Neutral |
Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
Oct-07-21 | Resumed | Jefferies | Buy |
Sep-09-21 | Upgrade | Stifel | Hold → Buy |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Mar-04-21 | Resumed | Guggenheim | Buy |
Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Aug-19-20 | Downgrade | Stifel | Buy → Hold |
Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jul-06-20 | Reiterated | Citigroup | Buy |
Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
Nov-12-19 | Initiated | SunTrust | Buy |
Oct-17-19 | Resumed | BofA/Merrill | Buy |
May-23-19 | Resumed | Citigroup | Buy |
Apr-09-19 | Resumed | Raymond James | Outperform |
Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Dec-14-18 | Initiated | Wolfe Research | Outperform |
Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
Aug-07-18 | Reiterated | Stifel | Buy |
Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc. Stock (BMRN) Latest News
Q2 2024 EPS Estimates for BioMarin Pharmaceutical Inc. Decreased by Analyst (NASDAQ:BMRN) - Defense World
Defense World
BMS’s Breyanzi Secures Fourth FDA Approval, for Follicular Lymphoma - BioSpace
BioSpace
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to Post Q2 2024 Earnings of $0.36 Per Share, Zacks Research Forecasts - MarketBeat
MarketBeat
Zacks Research Comments on BioMarin Pharmaceutical Inc.'s Q3 2024 Earnings (NASDAQ:BMRN) - Defense World
Defense World
Biopharma Layoff Tracker 2024: Bolt, Tenaya, BioMarin and More Cut Staff - BioSpace
BioSpace
BioMarin to reduce global workforce by approximately 170 employees - TipRanks.com - TipRanks
TipRanks
Biomarin Pharmaceutical Inc. Stock (BMRN) Financials Data
Biomarin Pharmaceutical Inc. (BMRN) Revenue 2024
BMRN reported a revenue (TTM) of $2.47 billion for the quarter ending March 31, 2024, a +13.74% rise year-over-year.
Biomarin Pharmaceutical Inc. (BMRN) Net Income 2024
BMRN net income (TTM) was $205.46 million for the quarter ending March 31, 2024, a +186.89% increase year-over-year.
Biomarin Pharmaceutical Inc. (BMRN) Cash Flow 2024
BMRN recorded a free cash flow (TTM) of $163.21 million for the quarter ending March 31, 2024, a +649.72% increase year-over-year.
Biomarin Pharmaceutical Inc. (BMRN) Earnings per Share 2024
BMRN earnings per share (TTM) was $1.07 for the quarter ending March 31, 2024, a +182.55% growth year-over-year.
About Biomarin Pharmaceutical Inc.
BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Cap:
|
Volume (24h):